These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31218710)

  • 1. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.
    Langlade C; Gouverneur A; Bosco-Lévy P; Gouraud A; Pérault-Pochat MC; Béné J; Miremont-Salamé G; Pariente A;
    Br J Clin Pharmacol; 2019 Sep; 85(9):2126-2133. PubMed ID: 31218710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena).
    Zhou L; Harrison-Woolrych M; Coulter DM
    Pharmacoepidemiol Drug Saf; 2003; 12(5):371-7. PubMed ID: 12899110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox
    Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD
    Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can social media data lead to earlier detection of drug-related adverse events?
    Duh MS; Cremieux P; Audenrode MV; Vekeman F; Karner P; Zhang H; Greenberg P
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1425-1433. PubMed ID: 27601271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
    Gemzell-Danielsson K; Schellschmidt I; Apter D
    Fertil Steril; 2012 Mar; 97(3):616-22.e1-3. PubMed ID: 22222193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undesirable effects related to oral antineoplastic drugs: comparison between patients' internet narratives and a national pharmacovigilance database.
    Pages A; Bondon-Guitton E; Montastruc JL; Bagheri H
    Drug Saf; 2014 Aug; 37(8):629-37. PubMed ID: 25027671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort Study of Psychiatric Adverse Events Following Exposure to Levonorgestrel-Containing Intrauterine Devices in UK General Practice.
    Slattery J; Morales D; Pinheiro L; Kurz X
    Drug Saf; 2018 Oct; 41(10):951-958. PubMed ID: 29785475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
    Auffret M; Labreuche J; Duhamel A; Deheul S; Cottencin O; Bordet R; Gautier S; Rolland B
    Drug Saf; 2017 Mar; 40(3):257-262. PubMed ID: 27988884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system--Mirena.
    Skrzypulec V; Drosdzol A
    Coll Antropol; 2008 Dec; 32(4):1059-68. PubMed ID: 19149209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices.
    Enzlin P; Weyers S; Janssens D; Poppe W; Eelen C; Pazmany E; Elaut E; Amy JJ
    J Sex Med; 2012 Apr; 9(4):1065-73. PubMed ID: 21492401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Informativity of French web forums for the evaluation of side effects of baclofen].
    Karapetiantz P; Lillo-Le Louët A; Bousquet C
    Therapie; 2019 Dec; 74(6):569-578. PubMed ID: 31253414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia.
    Vaughan D; Byrne P
    J Obstet Gynaecol; 2012 May; 32(4):372-4. PubMed ID: 22519484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand.
    Harrison-Woolrych M; Zhou L; Coulter D
    N Z Med J; 2003 Aug; 116(1179):U538. PubMed ID: 14513085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.